Bayer’s Monsanto unit goes before a Missouri state judge on Monday asking him to bless a $7.25 billion cash settlement that would draw a line under roughly 65,000 U.S. lawsuits alleging the weedkiller Roundup causes cancer. The hearing is the clearest test yet of whether Chief Executive Bill Anderson can convert his turnaround rhetoric into a clean legal exit, the 2018 Monsanto acquisition has already cost the company billions and the share price has never fully recovered.
The terms on the table
The proposed class deal, announced in February, offers tiered payouts of $10,000 to $165,000 to people who developed non-Hodgkin lymphoma after using Roundup at home or at work. The exact award turns on cancer severity, age at diagnosis, and exposure setting. Bayer puts up the cash; claimants give up the right to sue. The company denies liability and maintains glyphosate is safe, a position the U.S. Environmental Protection Agency backed in 2017. The World Health Organization’s cancer agency disagreed in 2015, calling the chemical a probable carcinogen.
The leverage question
Judge Timothy Boyer will hear from plaintiffs’ lawyers on both sides, some arguing the framework is the only sure path to compensation, others saying it traps current and future claimants into lowball awards. The settlement requires court approval but Boyer is not expected to rule from the bench. A previous $10 billion deal in 2020 resolved existing cases but left Bayer open to future filings; this one aims to close that door permanently. The company’s spokesman calls it fair and says it is supported by counsel representing tens of thousands of potential class members.
The scientific backdrop
The EPA does not require a cancer warning on Roundup’s label and is working on an updated human health risk assessment due late 2026. While the settlement has been pending, Bayer won a Supreme Court ruling on the adequacy of its warning label, undercutting a core legal theory in the pending cases. That decision shifted leverage toward the company, but only if the judge agrees the class structure is adequate for claimants who have not yet filed.
What to watch
If Boyer approves, Bayer finally caps a liability that has dogged the balance sheet for eight years. If he rejects it or demands changes, the overhang persists and Anderson’s turnaround timeline stretches further. The EPA’s late-2026 assessment could reopen the scientific debate either way. For now, the market is pricing in a resolution, but the judge has not signed.